Articles by Chris Burgess - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Chris Burgess

Is a Sample Size of n=6 a Magic Number?

Statistical analysis shows how much testing is needed to deliver a reliable estimate result.
Jun 2, 2014

Statistical analysis shows how much testing is needed to deliver a reliable estimate result.

Calibration of instruments: Is Your UV Spectrometer Accurate Enough

This article takes a statistical look at the calibration requirements for a UV spectrometer.
Jan 2, 2014

This article takes a statistical look at the calibration requirements for a UV spectrometer.

The Basics of Measurement Uncertainty in Pharma Analysis

How good is a reportable value?
Sep 2, 2013

How good is a reportable value?

Evaluating Risk-Based Specifications for Pharmaceuticals

The author discusses the purpose of analysis and testing and the implications for specifications and their underlying statistical distribution.
Jul 2, 2013

The author discusses the purpose of analysis and testing and the implications for specifications and their underlying statistical distribution.

Rounding Results for Comparison with Specification

The mysteries of rounding are exposed.
Apr 2, 2013

The mysteries of rounding are exposed; strict, unbiased rounding can be applied.

Calculating the Reportable Result from Retest Data

Two methods to evaluate retest data following out-of-specification results.
Feb 2, 2013

Two methods to evaluate retest data following out-of-specification results.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
FindPharma Custom Search
Click here